Results 221 to 230 of about 38,670 (289)

Ultra-processed foods and nutrition governance in Ecuador as a public health challenge. [PDF]

Lancet Reg Health Am
Mora-Domínguez J, Palacios-Mora DP, Calero-Cáceres W.   +2 more
europepmc   +1 more source

Should We Use Citizens' Assemblies to Make Health Policy?

Bioethics, EarlyView.
ABSTRACT This article assesses the normative case for using citizens' assemblies—small deliberative forums of randomly selected citizens—in health policymaking. Although they are increasingly popular, their normative justification remains underexplored. We reconstruct three possible rationales: Norman Daniels's ‘Accountability for Reasonableness’ (A4R)
Daniel Hutton Ferris, Johannes Kniess
wiley   +1 more source

EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours. [PDF]

Eur J Hum Genet
Gallon R, McCormick L, Saetta A, Albuquerque C, Butler S, Cranston T, Field J, McAnulty C, Silva P, Cheetham M, Sheils K, Burghel GJ.   +11 more
europepmc   +1 more source

Dealing With Conflicts in Medical Decisions: Epistemic Reasonable Disagreement Between Parents and Medical Staff

Bioethics, EarlyView.
ABSTRACT Many controversies in medical ethics, particularly those involving conflicts between parents and medical staff over decisions about child patients, are challenging to manage without causing significant polarization and communication issues. This is primarily because the parties involved—parents and physicians—operate at different epistemic ...
Chiara Innorta
wiley   +1 more source

Interleukin-6 as a predictive biomarker of systemic progression and therapeutic target in cutaneous plasmacytosis. [PDF]

An Bras Dermatol
Hong YY, Chen PY, New HT, Cai SQ.
europepmc   +1 more source

Between Safeguard and Constraint: Navigating Patient Autonomy in Protective Laws for Medical Assistance in Dying

Bioethics, EarlyView.
ABSTRACT There has been an increase in the number of jurisdictions legalizing or decriminalizing Medical Assistance in Dying (MAiD). Legal frameworks worldwide strive to balance respect for autonomy with regulatory safeguards that both operationalize voluntary choice and prevent access to MAiD in cases of remediable despair or coerced decision‐making ...
Janet Delgado, Iris Parra Jounou, Mar Vallès‐Poch, Ramón Ortega‐Lozano, María Victoria Martínez‐López, Luis Espericueta, Maria Isabel Tamayo‐Velázquez, David Rodríguez‐Arias, Rosana Triviño‐Caballero   +8 more
wiley   +1 more source

Late-Onset Systemic Lupus Erythematosus: Is It Really a Benign Disease? [PDF]

Cureus
Santacruz JC, Mantilla MJ, Pulido S, Agudelo C, Naranjo JA, Vergara OV, Londono J.   +6 more
europepmc   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. [PDF]

Br J Haematol
Speight B, Hamblin A, Talley P, Tsoulaki O, Robinson R, Dean P, Khorashad J, Kulasekararaj A, Godfrey AL, Mead AJ, McVeigh TP, Snape K, Consensus Meeting Attendees.   +12 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source